Morning Session of Day 3 of 2025 National Reimbursement Drug Negotiations Begins with AbbVie, Innovent Biologics, GeneScience, AstraZeneca and Others Entering Talks

Source: Cailian Press

【Third Morning Session of 2025 National Reimbursement Drug List Negotiations Begins: AbbVie, Innovent Bio, GenSci, AstraZeneca and Other Pharmaceutical Companies Participate】Cailian Press, November 1st — According to the on-site reports from Cailian Press at the 2025 National Reimbursement Drug List negotiation and the commercial insurance innovative drug price consultation, the third day of the 2025 National Reimbursement Drug List negotiations started at around 8 a.m., with AbbVie, AstraZeneca,Allist Pharmaceuticals, Kelun-Biotech, Innovent Bio, GenSci, Qilu Pharmaceutical,Amoytop BiotechRepresentatives from pharmaceutical companies such as Allist Pharmaceuticals, AstraZeneca, and Kelun-Biotech were present for negotiations in sequence. The reporter noted that Allist Pharmaceuticals, AstraZeneca, and Kelun-Biotech also participated in the negotiations yesterday, with AstraZeneca being involved for three consecutive days. (Reporters Chao Wu and Afeng Lu from Cailian Press)